BridgeBio Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Zemansky from Bank of America Securities maintained a Buy rating on the stock and has a $58.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Zemansky’s rating is based on BridgeBio Pharma’s promising growth prospects and strategic initiatives. The company has shown significant progress with its key product, Attruby, which is expected to drive substantial value. Despite some initial investor disappointment with recent quarterly results, the company’s strategy to enhance outreach and access is gaining traction, indicating potential for future growth.
Additionally, BridgeBio’s pipeline includes promising opportunities with encaleret and BBP-418, both of which are anticipated to be billion-dollar markets. The management’s confidence in encaleret’s effectiveness and the potential for BBP-418 to address unmet needs in its target population further supports the Buy rating. The overall risk/reward profile of BridgeBio’s stock remains attractive, justifying the positive outlook and price objective.
In another report released on September 29, Piper Sandler also maintained a Buy rating on the stock with a $68.00 price target.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBIO in relation to earlier this year.